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Abstract
Background:  Systematic surveillance for resistant malaria shows high level of resistance of
Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) across eastern and southern parts of
Africa. This study assessed in vivo SP efficacy after two years of use as an interim first-line drug in
Tanzania, and determined the rates of treatment failures obtained after 14 and 28 days of follow-up.
Methods:  The study was conducted in the Ipinda, Mlimba and Mkuranga health facilities in
Tanzania. Children aged 6–59 months presenting with raised temperature associated exclusively
with  P. falciparum (1,000–100,000 parasites per µl) were treated with standard dose of SP.
Treatment responses were classified according to the World Health Organization (WHO)
definition as Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure
(ETF), Late Clinical Failure (LCF) and Late Parasitological Failure (LPF) on day 14 and day 28.
Results: Overall 196 (85.2%) of 230 patients had ACPR on day 14 but only 116 (50.9%) on day 28
(57.7% after excluding new infections by parasite genotyping). Altogether 21 (9.1%) and 13 (5.7%)
of the 230 patients assessed up to day 14 and 39 (17.1%) and 55 (24.1%) of the 228 followed up to
day 28 had clinical and parasitological failure, respectively.
Conclusion:  These findings indicate that SP has low therapeutic value in Tanzania. The
recommendation of changing first line treatment to artemether + lumefantrine combination
therapy from early next year is, therefore, highly justified. These findings further stress that, for
long half-life drugs such as SP, establishment of cut-off points for policy change in high transmission
areas should consider both clinical and parasitological responses beyond day 14.
Background
There is controversy over the therapeutic life of sulfadox-
ine-pyrimethamine (SP) when used alone for the treat-
ment of uncomplicated malaria in Africa. Experts do not
all agree on which drug efficacy measurements more accu-
rately predict usefulness of a drug in a community. Some
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consider clearance of symptoms alone [1] or plus para-
sites by day 14, as advised by the World Health Organiza-
tion [Regional Office for Africa (WHO/AFRO)
Consultative Meeting on Antimalarial Policy in the Africa
Region, 14th–15th August 2003, Harare, Zimbabwe]. Oth-
ers regard clearance of both symptoms and parasites over
a much longer period as the most accurate measure of
drug effectiveness [2-4].
The assessment methodology has profound implications
in terms of treatment policy strategies. Attempts have
been made to define the cut-off points for changing first-
line malaria treatment. Using the old treatment response
classification criteria, the action period was due when a
combined Early Treatment Failure (ETF) and Late Treat-
ment Failure (LTF) were between 16 – 24% [4,5]. A couple
of years ago, WHO/AFRO recommended 15% clinical and
25% parasitological treatment failure rates at day 14 as
cut-off points for implementation of policy change in
intense transmission areas (WHO/AFRO consultative
meeting on antimalarial policy in the Africa region, 14th–
15th August 2003, Harare, Zimbabwe).
Systematic surveillance for efficacy of antimalarial drugs
shows increasing levels of Plasmodium falciparum resist-
ance to SP across eastern and southern parts of Africa
[6,7]. In 2001, Tanzania adopted SP as interim first-line
treatment for uncomplicated malaria while awaiting for
the results of different combination therapies trials. As
part of the National Malaria Control Programme
(NMCP), this study assessed in vivo SP efficacy after two
years of widespread use in Tanzania.
Methodology
The study was conducted from July to November 2003 in
the Ipinda (south-west), Mlimba (south-east) and
Mkuranga (east) health facilities in Tanzania. Malaria
transmission in these areas is perennial with peaks
between May and July. A slightly modified WHO antima-
larial drug efficacy testing protocol [8] was used, so as to
conform with another study that was being conducted at
the same time under the same project framework in Papua
New Guinea, in areas with lower levels of endemicity.
Children aged 6–59 months presenting with raised tem-
perature (37.5°C–39.5°C) associated with P. falciparum
parasitaemia between 1,000–100,000 parasites per µl
were recruited. Exclusion criteria and other procedures
were as detailed in the protocol [8]. Patients were treated
(under observation) with a standard dose of SP (Fansidar®
Roche), i.e 1.25 mg/kg of pyrimethamine and 25 mg/kg of
sulfadoxine. The responses were classified according to
the new WHO definition as ACPR, ETF, LCF and LPF at
day 14 and day 28 [8].
Treatment failures rates were corrected after genotyping
the msp2 locus to detect new infections. Extensive diversity
in this locus has been observed with over 84 allelic vari-
ants in south-eastern Tanzania [9,10] and other investiga-
tors observed high genotype complexity with an average
of 4.9 genotypes per asymptomatic individual in eastern
Tanzania [11]. These observations are suggestive that msp2
alone may sufficiently discriminate recrudescence from
reinfection in Tanzania. It has previously been shown that
analysis of msp2 locus alone can effectively distinguish
recrudescence from reinfection in Uganda [12]. The clini-
cal and molecular data were combined and analysed
using Stata version 8.0 (Stata Corporation Inc, Texas,
USA).
Results
A total of 241 patients were recruited, of which 13 were
lost to follow-up. Table 1 summarizes patient age and
clinical parameters recorded on admission day by site.
Table 2 provides details of treatment outcome by site. On
day 28, only 116 (50.9%) of the 228 patients showed
ACPR. Molecular genotyping showed that 27/112
(24.5%) recurrent infections were due to re-infections,
therefore were excluded from the analysis and recorded as
withdrawn. Hence, PCR-corrected ACPR was 116/201
(57.7%). 196 (85.2%) of the 230 patients had ACPR by
day 14.
The total clinical failure by day 14 and 28 was observed in
21 (9.1%) out of 230 and 39 (17.1%) out of 228 patients,
respectively. 13 (5.7%) and 55 (24.1%) of the patients
had LPF by day 14 and 28, respectively. Thus 34 (14.9%)
Table 1: Mean age, temperature, haemoglobin and parasite density on admission day
Site Means
Weight in kg(SD)1 Age in years (SD)1 Temperature in °C (SD)1 Hb1 in g/dl (SD)1 parasites/µl (SD)
Ipinda (n = 73) 10.7(2.9) 1.7(1.3) 38.4(1.0) 9.4(1.6) 31'499 (30,260)
Mlimba (n = 75) 11.0(2.9) 1.7(1.4) 38.3(0.9) 9.0(1.6) 53,206(30,782)
Mkuranga (n = 93) 10.9(3.7) 1.3(1.0) 38.7(0.8) 8.6(1.9) 44,877(38,572)
Hb = haemoglobin; SD = standard deviationMalaria Journal 2005, 4:55 http://www.malariajournal.com/content/4/1/55
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out of 230 and 112 (49.1%) out of 228 patients had over-
all treatment failure by day 14 and 28, respectively. After
genotyping recurrent infections day-28 treatment failures
decreased to 85 (42.3%). In this study Mkuranga recorded
the highest rates of both PCR-adjusted and unadjusted
treatment failures followed by Mlimba and Ipinda.
Discussion
In 2001 Tanzania replaced chloroquine with SP as interim
first-line antimalarial drug. Prior to this change, baseline
clinical trials with SP had been conducted throughout the
country using the 14 day follow-up protocol, and indi-
cated an average efficacy of 86% on day 14. These findings
paved the way for the malaria treatment policy change
[13] and SP is still used as first line antimalarial drug in
Tanzania. The present study assessed SP efficacy (using a
28 day follow-up) in three sites in Tanzania after two years
of use as first-line antimalarial drug. With this extended
period of follow-up, half of the patients (49.1%) failed
treatment. Even when new infections were taken into
account by genotyping, the overall treatment failure rate
(42.3%) was still high. This level of resistance is close to
that observed in Muheza (45%), an area of high SP resist-
ance in Tanzania [14].
Restricting our analysis to outcomes at day 14 would have
led to misleadingly low clinical (9.1%) and parasitologi-
cal (5.7%) treatment failure rates with the overall treat-
ment failure (14.9%) being equal to that recorded at
baseline prior to policy change. Using a shorter follow-up
period, another study in parts of Tanzania also recorded
an overall SP treatment failure of only 9.2% [15]. Accord-
ing to WHO/AFRO proposed thresholds for policy change
(i.e 15% and 25%, respectively), these failure levels would
still be considered acceptable. Retention of SP clinical effi-
cacy at day 14 after 10 years of its use as first-line drug has
been demonstrated in Malawi [1]. However, extending
the follow-up to day 28 the total failure was as high as
66%. Even at day 14 the clinical and total failure rates
were far above 15% and 25%, respectively. As in Malawi,
the majority of the recurrent infections in our study were
LPFs observed between day 14 and 28. The new WHO effi-
cacy testing protocol [8] recommends follow up for 28
days for drug with long half-life such as SP, if genotyping
can be done to distinguish recrudescence from re-infec-
tions. When efficacy assessment is based only on clear-
ance of symptoms in the first 14 days, the level of parasite
resistance can be grossly underestimated. It is widely
accepted that clearance of both parasitaemia and symp-
toms is the most accurate measure of the intrinsic resist-
ance of the parasite to a drug [2-4]. The resistant parasite
that is apparently causing asymptomatic infection in LPF
is likely to lead in the short-term to a new clinical episode
[14] and/or to anaemia, depending on the immunity of
the subject.
Our observations show that SP efficacy in Tanzania is
compromised and fully justify the recent decision to
review the current malaria treatment policy from early
next year in favour of artemether + lumefantrine combina-
tion therapy. This recommendation should be imple-
mented at a large scale as soon as possible. Such a change
would be welcome to protect the use of SP in its indica-
tion for the intermittent preventive treatment of pregnant
women (IPTp). Indeed, it is at present the only drug that
can be used for IPTp purpose because of its good safety
profile. As far as methodology is concerned, the findings
stress that cut-off points for malaria treatment policy
Table 2: Sulfadoxine-pyrimethamine treatment outcomes
Results no. of included 
patients
LF and 
corr.
Evaluable 
patients
ACPR 
n (%)
ETF
n (%)
LCF
n (%)
Total CF
n (%)
LPF
n (%)
Overall TF
n (%)
At D14
Ipinda 73 1 72 62(86.1) 7(9.7) 2(2.8) 9(12.5) 1(1.4) 10(13.9)
Mlimba 75 3 72 63(87.5) 3(4.3) 4(5.7) 7(9.1) 2(2.9) 9(12.9)
Mkuranga 93 7 86 71(82.6) 3(3.5) 2(2.3) 5(6.9) 10(11.6) 15(17.4)
Total 241 11 230 196(85.2) 13(5.7) 8(3.5) 21(9.1) 13(5.7) 34(14.9)
At D28
Ipinda 72 0 72 44(61.1) 7(9.7) 5(6.9) 12(16.7) 16(22.2) 28(38.9)
Mlimba 72 2 70 34(48.6) 3(4.3) 9(12.9) 12(17.1) 24(34.3) 36(51.4)
Mkuranga 86 0 86 38(44.2) 3(3.5) 12(13.9) 15(17.4) 33(38.4) 48(55.8)
Total 230 2 228 116(50.9) 13(5.7) 26(11.4) 39(17.1) 55(24.1) 112(49.1)
At D28 PCR-corrected
Ipinda 72 6 66 44(66.7) 7(9.7) 5(6.9) 12(16.7) 10(13.9) 22(33.3)
Mlimba 70 10 60 34(56.7) 3(4.3) 5(7.1) 8(11.4) 18(25.7) 26(43.3)
Mkuranga 86 11 75 38(50.7) 3(3.5) 8(9.3) 11(12.8) 26(30.2) 37(49.3)
Total 228 27 201 116(57.7) 13(5.7) 18(7.9) 31(13.6) 54(23.7) 85(42.3)
ACPR = Adequate Clinical and Parasitological Response; TF = Treatment failure, ETF = Early Treatment Failure, LCF = Late Clinical Failure; LPF = 
Late Parasitological Failure; CF = Clinical failure, n = Sample Size; TF = Treatment failure, FP = Lost to Follow-up, corr. = correctedPublish with BioMed Central    and   every 
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change in high transmission areas should consider both
clinical and parasitological responses beyond day 14, cou-
pled with distinction of recrudescence from re-infection
using molecular genotyping.
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